Active Biotech AB - Interim report January - June 2017
10 August 2017 - 4:30PM
Second quarter in brief
-
In April, the US Food and Drug Administration
(FDA) granted Orphan Drug Designation for tasquinimod for the
treatment of multiple myeloma
-
The primary clinical endpoint from the Phase III
trial of laquinimod in RRMS (CONCERTO study) was not met. The
secondary endpoints (brain atrophy, relapse rate and MRI-data) were
achieved and in line with previous studies
-
Out-licensing activities are continuing for
tasquinimod, paquinimod and SILC
Events after the end of the
period
-
Helén Tuvesson succeeds Tomas Leanderson as
President & CEO of the company July 1, 2017
-
In July, a patent application for the use of
ANYARA in combination with PD-1 inhibitors for the treatment of
cancer was published on WIPO's (World Intellectual Property
Organization) website www.wipo.int
Financial
summary
SEK M |
April-June |
Jan.-June |
Full-year |
|
2017 |
2016 |
2017 |
2016 |
2016 |
|
|
|
|
|
|
Net
sales |
5.1 |
3.9 |
9.8 |
7.9 |
19.0 |
Operating
loss |
-23.1 |
-14.5 |
-37.7 |
-30.6 |
-55.1 |
Loss for
the period |
-24.4 |
-15.5 |
-40.2 |
-32.3 |
-59.6 |
Loss per
share, before and after dilution (SEK) |
-0.25 |
-0.17 |
-0.42 |
-0.36 |
-0.65 |
Cash and
cash equivalents (at the end of the period) |
|
|
47.7 |
57.4 |
77.7 |
For further
information, please contact:
Helén Tuvesson,
President & CEO
Tel: +46 (0)46-19 21 56
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
|
Active
Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: 046 (0)46-19 20 00
|
The report is also available at
www.activebiotech.com.
Active Biotech AB - Interim report
January – June 2017
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Actividentity Corp (MM) (NASDAQ): 0 recent articles
More Active Biotech News Articles